Flow Cytometry, Immunoassay Automation, and Molecular Methods

Flow cytometry, automated immunoassay, and molecular testing use different signals, but their workflows share a rule: a result is interpretable only when specimen preparation, selective recognition, detection, controls, and data analysis are all performed as intended. Automation can make these steps faster and more reproducible. It cannot make an unsuitable specimen or an unvalidated decision rule reliable.

Flow cytometry

A flow cytometer measures light scatter and fluorescence from cells or particles as they pass an interrogation point. Each recorded particle is an event. The instrument does not identify an event by appearance. Identity comes from a validated combination of specimen preparation, scatter, fluorescence markers, controls, and gating.

Fluidics, optics, and electronics

Forward scatter often correlates with particle size within a fixed optical system and specimen preparation. Side scatter often correlates with refractive and internal complexity. Neither parameter is an absolute measurement of size or granularity, and scatter alone cannot establish lineage. Fluorochrome-labeled antibodies or probes add measurements tied to selected targets.^1,2

A conventional cytometer sends emission through filters to separate detectors. Fluorochrome spectra overlap, so signal from one label can enter another detector. Compensation estimates that spillover from suitable single-stained controls and subtracts it mathematically. A spectral cytometer records a wider emission signature and uses spectral unmixing to estimate each fluorochrome contribution. Both methods require controls matched to the fluorochromes, instrument configuration, and relevant autofluorescence. A poor control produces a mathematically precise wrong answer.

Plots, gates, and controls

A histogram displays one parameter against event count. A dot or density plot displays two parameters. A gate is an analysis boundary selecting events for another measurement or calculation. Gates should follow a documented sequence that addresses acquisition time, debris, singlets, viable events when applicable, and the population-defining markers. The order matters because an excluded event cannot reappear downstream.

Common controls answer different questions:

• Instrument performance particles track alignment, detector response, background, and day-to-day stability.
• An unstained specimen shows autofluorescence and baseline signal.
• Single-stained controls support compensation or unmixing.
• Fluorescence-minus-one controls can show spread from the other fluorochromes near a difficult gate.
• Viability reagents identify cells with compromised membranes when viability affects interpretation.
• Assay-specific positive and negative materials challenge staining, processing, and analysis.

An isotype control can investigate selected nonspecific binding questions. It does not reproduce every source of background and cannot set every positive gate by itself. Controls should resemble the test specimen and pass through the steps they are meant to assess.

Anticoagulant, transport, storage, lysis, fixation, staining time, and acquisition stability are assay-specific. Fixed hour limits cannot be transferred between panels or specimen types. The laboratory follows the validated collection and stability instructions and records deviations.

Enumeration and immunophenotyping

A dual-platform absolute count combines a cytometric percentage with an absolute count from a hematology analyzer:

Absolute subset count = absolute parent-population count × subset fraction

If the absolute lymphocyte count is 1,800 cells/µL and 16% of the validated lymphocyte gate meets the CD3/CD4 definition, the calculated subset count is 288 cells/µL. Uncertainty from both instruments and the gating denominator affects the result.

Single-platform methods derive the count in the cytometer using a known bead concentration, a measured sample volume, or another validated counting method. They avoid combining two separately measured patient values, but bead recovery, pipetting, acquisition volume, and event loss still require control. CLSI H42-A2 covers specimen handling, staining, instrument calibration, analysis, and reporting for lymphocyte-subset and CD34 enumeration; the document was reaffirmed in 2017.³

A marker is rarely unique to one cell or disease. Intensity, maturation, antigen combinations, specimen type, morphology, genetics, and clinical context determine meaning. A single familiar pattern cannot substitute for the full validated panel. HIV Testing and Monitoring owns CD4 interpretation; Immunology, Hematology, Blood Banking, and other subject modules own their disease-specific panels and clinical decisions.

Automated immunoassay systems

An automated immunoassay analyzer can perform specimen aspiration, reagent addition, mixing, incubation, bound-free separation when required, signal generation, detection, calculation, and transmission to the laboratory information system. A batch system groups specimens for one assay. A random-access system schedules different assays for different specimens as orders arrive. Actual throughput depends on incubation times, reagent capacity, maintenance, repeats, dilutions, and instrument scheduling.

The analytic sequence provides a troubleshooting map:

1. The probe or disposable tip identifies and aspirates the specimen.
2. Reagent identity, lot, volume, storage, and onboard stability are checked.
3. The reaction is mixed and incubated under controlled time and temperature.
4. A heterogeneous assay separates bound from free label and washes the reaction vessel.
5. The detector measures absorbance, fluorescence, chemiluminescence, electrochemiluminescence, or another validated signal.
6. Software applies calibration, flags, dilution rules, and the reportable result.

Clot detection, liquid-level sensing, pressure monitoring, barcodes, disposable tips, and wash cycles reduce specific risks. Each safeguard has a detection limit. Carryover can come from a sample probe, reagent probe, mixer, wash station, reaction vessel, or software sequence. An acceptable global carryover check does not prove that every high-low analyte pair is harmless.

In a sandwich assay, signal commonly increases with captured measurand. In a competitive assay, signal commonly decreases as patient measurand displaces labeled material. The analyzer must apply the correct calibration model and flags. Antigen excess, endogenous antibodies, biotin exposure, matrix effects, and cross-reactivity depend on the assay design. Automation does not remove them. Serologic Procedures and Test Results covers immunoassay formats and interpretation.^1,2

Before patient reporting, verify specimen and reagent handling, carryover where relevant, calibration, precision, bias, measuring interval, reference intervals or decision limits, units, dilution and reflex rules, flags, critical-result handling, and interface transmission. Train operators on loading, maintenance, error recovery, and result review. Quality Control, Method Evaluation, and Quality Management covers the shared verification and quality framework.

Molecular testing begins before amplification

A molecular result depends on the target form, specimen, collection device, transport, storage, pretreatment, extraction, and input amount. DNA, RNA, intact cells, cell-free nucleic acid, and fixed tissue need different processes. CLSI MM13, second edition, provides current guidance for specimen collection, transport, preparation, storage, isolation, and evaluation across molecular methods.⁴

Extraction and purification

Every extraction combines disruption or lysis with removal of substances that inhibit or interfere with the downstream method.

Extraction efficiency depends on specimen matrix, target location, target length, input, lysis, and elution volume. A method that yields abundant genomic DNA may recover cell-free DNA or RNA poorly. Formalin-fixed paraffin-embedded tissue often contains cross-linked and fragmented nucleic acid. Fixation, block age, tumor selection, extraction, and assay target length all influence usable yield. RNA workflows also control ribonuclease exposure and may need a reverse-transcription step.

Mitochondrial targets can be measured from a total-nucleic-acid extract or after a validated enrichment step. The chosen workflow must control recovery, heteroplasmy detection, and interference from homologous nuclear mitochondrial sequences. A separate mitochondrial isolation is one option, not a requirement for every mitochondrial assay.^4,7

Quantity, purity, and integrity

Ultraviolet absorbance at 260 nm estimates total nucleic acid under a defined path length and background correction. Absorbance ratios such as A₂₆₀/A₂₈₀ can reveal gross contamination, but an “acceptable” ratio does not prove purity, integrity, or assay suitability. Buffers and low concentration can distort the ratio.

Fluorometric dyes can be more selective for double-stranded DNA, single-stranded DNA, or RNA and are useful at lower concentrations. Gel or capillary electrophoresis and microfluidic systems show size distribution and degradation. None of these measurements guarantees amplifiability. The downstream assay defines acceptable concentration, integrity, fragment distribution, and inhibitor tolerance.^1,2,4

Hybridization and nucleic-acid separation

A nucleic-acid probe recognizes a complementary sequence. Temperature, salt concentration, probe length, base composition, formamide, and wash conditions determine stringency. High stringency favors closely matched duplexes; low stringency permits more mismatches. Probe design must also address homologous sequences, pseudogenes, repetitive regions, and secondary structure. A strong signal can still come from an unintended complementary sequence.

Agarose gels separate a broad range of nucleic-acid fragments according to size, with concentration, voltage, buffer, and run time setting useful resolution. Polyacrylamide provides finer resolution for small fragments. Capillary electrophoresis uses a sieving polymer and fluorescent detection for fragment analysis and Sanger sequencing. Fluorescent stains and ultraviolet or visible-light systems have product-specific binding, sensitivity, and hazards; follow the safety data and validated detection method.

Pulsed-field gel electrophoresis periodically changes field direction to separate very large DNA fragments. It remains a useful principle and a historical bacterial-subtyping method. It is no longer the primary PulseNet method: all 50 U.S. state public-health laboratories completed the transition from PFGE to whole-genome sequencing for surveillance and outbreak detection in 2019.⁸

Polymerase chain reaction

PCR amplifies a region between two primers. A reaction contains template, forward and reverse primers, deoxynucleotide triphosphates, a thermostable polymerase, magnesium and buffer, and any assay-specific probe or control. Cycling repeats three functions:

1. Denaturation separates double-stranded template.
2. Annealing lets primers bind complementary targets.
3. Extension lets polymerase synthesize from each primer’s 3′ end.

Perfect doubling would produce 2^N copies from one starting copy after N cycles. Real reactions lose efficiency through reagent limits, inhibitors, competing products, and changing kinetics. The ideal expression explains exponential amplification; it is not a quantitative calibration model.

Real-time PCR can use a double-stranded-DNA-binding dye or a sequence-specific probe. A dye reports any compatible double-stranded product, including primer dimers. A hydrolysis probe adds recognition between the primers and separates reporter from quencher during extension. Other probe designs use hybridization-dependent fluorescence or energy transfer. Assay specificity depends on the entire primer, probe, cycling, and analysis system, not a simple ranking of dye names.

The quantification cycle, written Cq and also called Ct by some platforms, occurs earlier when more amplifiable target is present. Comparing Cq values across runs or assays requires compatible efficiency, threshold, calibration, and input. MIQE 2.0 updates the information needed to evaluate quantitative real-time PCR experiments, including sample processing, assay specificity, efficiency, controls, data analysis, and reporting.⁵

Controls that localize failure

A positive amplification control added after extraction cannot prove extraction worked. A negative-template control cannot reveal contamination introduced before amplification setup. Control placement should span the failure that the control is meant to detect.

Pre-amplification reagent preparation, specimen processing, amplification, and post-amplification analysis use separated space, dedicated supplies, controlled movement, and cleaning validated for the target and surface. Uracil-N-glycosylase systems can reduce carryover from compatible uracil-containing amplicons. They do not remove native target or amplicons made without that chemistry. Ultraviolet exposure and chemical decontamination also have material, shadowing, concentration, contact-time, and safety limits. CLSI MM03 remains an archived, technically valid source for amplification controls, inhibitors, false-positive control, and quality assurance in infectious-disease molecular testing.⁶

Sequencing

Sanger sequencing

Sanger sequencing extends a primer with ordinary nucleotides and fluorescent chain-terminating dideoxynucleotides. Terminated fragments form a nested size series. Capillary electrophoresis separates them, and detector color produces an electropherogram. Base-call quality can fall near the primer, through long homopolymers, across mixed templates, and later in a read. A heterozygous insertion or deletion can create overlapping sequence downstream.

Sanger sequencing remains useful for limited-content assays, fill-in of poorly covered regions, and selected confirmation strategies. It is not a universal reference method for every variant or specimen. The orthogonal method must have adequate sensitivity for the allele fraction, variant type, and sequence context.⁷

Targeted incorporation and methylation methods

Pyrosequencing detects pyrophosphate released as each supplied nucleotide is incorporated, then converts the coupled reaction to light. It supports short targeted reads and quantitative applications such as selected methylation measurements. Nucleotide-dispensing order, background, incomplete extension, and homopolymer length affect the signal.

Bisulfite treatment converts most unmethylated cytosine to uracil, which is read as thymine after amplification, while 5-methylcytosine is generally retained as cytosine. Conversion efficiency, DNA degradation, incomplete conversion, and sequence-dependent amplification require controls. The sequence comparison estimates methylation only at loci covered by the validated assay.^1,2

High-throughput sequencing

A clinical next-generation sequencing workflow includes:

1. Extract and assess nucleic acid.
2. Create a library with platform adapters and sample identifiers.
3. Enrich selected regions by amplification or hybrid capture when the assay is targeted.
4. Generate sequence reads with the validated platform chemistry.
5. Demultiplex, perform quality filtering, and align reads to a stated reference.
6. Call the supported variant classes and apply validated filters.
7. Annotate, classify, interpret, review, and report within the assay’s scope.

Fluorescent reversible-terminator systems image incorporated bases cycle by cycle. Semiconductor systems sense hydrogen ions released during incorporation. Platform chemistry affects error patterns, read structure, and detectable variants. Library fragment length, read depth, uniformity, strand balance, mapping quality, allele fraction, contamination, index errors, and difficult sequence regions all influence performance.

Bioinformatics is part of the measurement procedure. Software versions, reference builds, databases, parameters, and report rules need change control and validation. A high average depth cannot rescue a clinically important exon with no usable reads, and a negative report does not exclude variant classes outside the validated assay. CLSI MM09, third edition, provides current recommendations for design, development, validation, reporting, and continual quality management of human Sanger and high-throughput sequencing tests.⁷

Microbiology, Hematology, Immunology, Chemistry, Blood Banking, and other subjects own target selection and clinical interpretation. This module owns the shared instrument and control logic that shows whether the cellular or molecular result is technically supportable.

References

1. Bishop ML, Fody EP, Van Siclen C, Mistler JM, Moy M. Clinical Chemistry: Principles, Techniques, and Correlations. 9th ed. Jones & Bartlett Learning; 2023.
2. Rifai N, Chiu RWK, Young I, Burnham CAD, Wittwer CT, eds. Tietz Textbook of Laboratory Medicine. 7th ed. Elsevier; 2023.
3. Clinical and Laboratory Standards Institute. Enumeration of Immunologically Defined Cell Populations by Flow Cytometry. 2nd ed. CLSI guideline H42-A2. Clinical and Laboratory Standards Institute; 2007. Reaffirmed June 2017. Accessed August 31, 2026.
4. Clinical and Laboratory Standards Institute. Collection, Transport, Preparation, and Storage of Specimens for Molecular Methods. 2nd ed. CLSI guideline MM13. Clinical and Laboratory Standards Institute; 2020. Accessed August 31, 2026.
5. Bustin SA, Ruijter JM, van den Hoff MJB, et al. MIQE 2.0: revision of the Minimum Information for Publication of Quantitative Real-Time PCR Experiments guidelines. Clin Chem. 2025;71(6):634-651. doi:10.1093/clinchem/hvaf043.
6. Clinical and Laboratory Standards Institute. Molecular Diagnostic Methods for Infectious Diseases. 3rd ed. CLSI report MM03. Clinical and Laboratory Standards Institute; 2015. Archived and retained as technically valid. Accessed August 31, 2026.
7. Clinical and Laboratory Standards Institute. Human Genetic and Genomic Testing Using Traditional and High-Throughput Nucleic Acid Sequencing Methods. 3rd ed. CLSI guideline MM09. Clinical and Laboratory Standards Institute; 2023. Accessed August 31, 2026.
8. Centers for Disease Control and Prevention. PulseNet timeline. Accessed August 31, 2026.